 |
424 Diseases |  |
808 Trials |
|
808 Trials |  |
14431 News |  |
| «12...136137138139140141142143144145146...236237» |
- irinotecan / Generic mfg.
[VIRTUAL] TCOG T5217 trial: A phase II randomized study of SLOG versus modified FOLFIRINOX as the first-line treatment in locally advanced or metastatic pancreatic ductal adenocarcinoma. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1555;
P2
SLOG could achieve comparable but numerically better ORR, and median PFS and OS as compared to mFOLFIRINOX in patients of advanced PDAC . SLOG can be an alternative first-line regimen for advanced PDAC patients.
- Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
[VIRTUAL] Alternating gemcitabine/nab-paclitaxel (GA) and 5-FU/leucovorin/irinotecan (FOLFIRI) as first-line treatment for de novo metastatic pancreatic cancer (MPC): Safety and effect. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1537;
SLOG can be an alternative first-line regimen for advanced PDAC patients. 1) Alternating GA/ FOLFIRI in MPC has a more favorable toxicity profile than standard regimens 2) Med OS appears superior to GA and competitive with FOLFIRINOX ; longer term (18/24 mo ) OS seemed particularly encouraging 3) ≥ 48 wks Rx and ECOG PS 0 were prognostically significant 4) Further investigation using this regimen including a) randomized comparisons, b) incorporation of molecular data and c) addition of additional agents seems indicated Updated survival data will be presented at the meeting
- irinotecan / Generic mfg., gemcitabine / Generic mfg.
[VIRTUAL] Modified FOLFIRINOX versus S-1 as second-line chemotherapy in patients with gemcitabine-failed metastatic pancreatic cancer: A randomized phase III trial (MPACA-3). () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1531;
Clinical Trial Registry Number: KCT0003534 Background: Modified FOLFIRINOX (mFOLFIRINOX) consisting of 5-fluorouracil/leucovorin, irinotecan, and oxaliplatin has been assessed as second-line treatment of patients with advanced pancreatic cancer in retrospective and phase II studies . mFOLFIRINOX as second-line treatment in mPAC patients failed to gemcitabine-based chemotherapy demonstrated a survival benefit versus S-1 alone with acceptable toxicities.
- Tuoyi (toripalimab) / Shanghai Junshi Biosci, Coherus
[VIRTUAL] A phase II trial of lenvatinib plus toripalimab and hepatic arterial infusion chemotherapy as a first-line treatment for advanced hepatocellular carcinoma (LTHAIC study). () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1495;
P2
Combination treatment with lenvatinib and toripalimab plus HAIC showed promising antitumor activity and manageable toxicity in patients with advanced HCC . Further randomized, controlled trials are warranted to validate our findings.
- Tuoyi (toripalimab) / Shanghai Junshi Biosci, Coherus
[VIRTUAL] Phase II study of perioperative toripalimab in combination with FLOT in patients with locally advanced resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1463;
P2
Perioperative toripalimab in combination with FLOT showed promising efficacy with high pCR and MPR rate and well tolerated safety profile in patients with resectable gastric/GEJ adenocarcinoma . This combination regimen might present a new option for patients with locally advanced, resectable gastric/GEJ adenocarcinoma.
- paclitaxel / Generic mfg.
[VIRTUAL] Final survival results from a multicenter, randomized phase II trial of intravenous paclitaxel plus FOLFOX (ivPOF) and/or intraperitoneal paclitaxel plus FOLFOX (ipPOF) versus mFOLFOX6 as first-line treatment of advanced gastric cancer (AGC): SYLT/FNF 004. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1454;
P2
Subjects were randomly assigned to one of three treatments: intravenous paclitaxel 135 mg/m2 + mFOLFOX6 omitting the 5-FU bolus (ivPOF); intraperitoneal paclitaxel 80 mg/m2 + mFOLFOX6 omitting the 5-FU bolus (ipPOF); or mFOLFOX6 (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2 followed by 5-FU 400 mg/m2 bolus and 5-FU 2400 mg/m2 as a 46-hour continuous infusion)... POF, ivPOF or ipPOF improved both PFS and OS compared with mFOLFOX6, with similarly manageable adverse effects.
- oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., docetaxel / Generic mfg.
[VIRTUAL] Real-world data (RWD) reveals benefit for adjuvant chemotherapy with docetaxel, oxaliplatin and fluorouracil/leucovorin (FLOT) is limited to those with tumour regression grade (TRG) ≥3 in oesophago-gastric cancer (OGC). () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1452;
Our analyses suggest that only pts with TRG >3 following naFLOT + surgery benefit from adjuvant FLOT . Prospective randomised studies are required to confirm whether pts with TRG 1/2 require treatment with aFLOT.
- Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
[VIRTUAL] Randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer (JCOG1407). () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1428;
The 1-year OS of the primary endpoint in GnP was better than mFOLFIRINOX, but mFOLFIRINOX achieved longer survival in 2-year OS . It is required to confirm longer OS and safety profiles which regimen should be selected as a standard regimen in LAPC.
- Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
[VIRTUAL] Liposomal irinotecan (nal-IRI) in combination with fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic biliary tract cancer (BTC) after progression on gemcitabine plus cisplatin (GemCis): Multicenter comparative randomized phase 2b study (NIFTY). () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1417;
P2
Nal-IRI plus 5-FU/LV should be considered as standard second-line therapy for advanced BTC . ClinicalTrials.gov identifier: NCT03524508
- [VIRTUAL] Neo-AEGIS (Neoadjuvant trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Preliminary results of phase III RCT of CROSS versus perioperative chemotherapy (Modified MAGIC or FLOT protocol). (NCT01726452). () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1413;
P3
Oncologic and operative outcomes were consistent with optimum modern benchmarks . These data strongly suggest non-inferiority and support equipoise in decision making in modern practice.
- | varlitinib (ASLAN001) / ASLAN Pharma
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy: ASLAN001 in Combination With Oxaliplatin and Capecitabine or Oxaliplatin and 5-FU With Leucovorin (clinicaltrials.gov) - Apr 28, 2021
P1, N=60, Active, not recruiting, Sponsor: National Cancer Centre, Singapore
These data strongly suggest non-inferiority and support equipoise in decision making in modern practice. Recruiting --> Active, not recruiting | Trial completion date: Jun 2020 --> Jun 2021 | Trial primary completion date: Jun 2020 --> Jun 2021
- |||| napabucasin (BBI608) / Sumitomo Pharma
Trial completion date, Trial primary completion date, Combination therapy, Metastases: CanStem303C trial: A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 28, 2021
P3, N=1253, Active, not recruiting, Sponsor: Sumitomo Dainippon Pharma Oncology, Inc
Recruiting --> Active, not recruiting | Trial completion date: Jun 2020 --> Jun 2021 | Trial primary completion date: Jun 2020 --> Jun 2021 Trial completion date: Feb 2022 --> May 2021 | Trial primary completion date: Feb 2022 --> May 2021
- || leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
Clinical, Journal: A prospective, crossover randomized trial of the optimal timing for leucovorin rescue after high-dose methotrexate management in adult non-Hodgkin's lymphoma patients. (Pubmed Central) - Apr 28, 2021
No bleeding occurred and the incidence of fever with grade III/IV neutropenia was low with no difference observed between the two groups. We recommend that with the HDMTX generally used most adult patients with NHL may have greater therapeutic benefit and acceptable toxicity with their LV rescue started at 24 h instead of 18 h.
- || Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Clinical, Retrospective data, Journal: Nab-paclitaxel: An effective third-line chemotherapy in patients with advanced, unresectable gallbladder cancer. (Pubmed Central) - Apr 28, 2021
This retrospective study was conducted to present the treatment outcomes with three lines of chemotherapies in a subset of patients with advanced, unresectable GBC with the primary objective to determine the response rates with nab-paclitaxel as the third-line chemotherapy after failure of the first-line gemcitabine and platinum and the second-line FOLFOX-4 (oxaliplatin, leucovorin and 5-FU) therapy...The dose of gemcitabine and cisplatin or carboplatin was 1 g/m on days 1 and 8 and 75 mg/m (or target AUC of 5) on day 1, in a 21-day cycle...Common Terminology Criteria (CTC) grade 3 or 4 haematological toxicities were observed in 28.6, 38.1 and 23.8 per cent of patients on gemcitabine/platinum, FOLFOX-4 and nab-paclitaxel therapy, respectively. Our study suggests the clinical benefit of nab-paclitaxel chemotherapy in prolonging OS in a selected subgroup of advanced, unresectable GBC patients after failure of the first-line gemcitabine and platinum and the second-line FOLFOX-4 therapy.
- || napabucasin (BBI608) / Sumitomo Pharma
Enrollment closed, Enrollment change: Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols (clinicaltrials.gov) - Apr 28, 2021
P1, N=7, Active, not recruiting, Sponsor: Sumitomo Dainippon Pharma Oncology, Inc
Our study suggests the clinical benefit of nab-paclitaxel chemotherapy in prolonging OS in a selected subgroup of advanced, unresectable GBC patients after failure of the first-line gemcitabine and platinum and the second-line FOLFOX-4 therapy. Enrolling by invitation --> Active, not recruiting | N=10 --> 7
- | New P2 trial, Metastases: NOAHS-ARC: No Operation After Short Course Radiotherapy Followed By Consolidation Chemotherapy In Locally Advanced Rectal Cancer (clinicaltrials.gov) - Apr 27, 2021
P2, N=73, Recruiting, Sponsor: Servicio de Salud Metropolitano Sur Oriente
- || Avastin (bevacizumab) / Roche
Clinical, Journal, HEOR: Cost-Effectiveness of Capecitabine + Irinotecan Versus Leucovorin + Fluorouracil + Irinotecan in the Second-line Treatment of Metastatic Colorectal Cancer in China. (Pubmed Central) - Apr 27, 2021
Enrolling by invitation --> Active, not recruiting | N=10 --> 7 Based on the results of this study, mXELIRI was found to be a cost-effective alternative to FOLFIRI as a second-line treatment of mCRC in patients in China.
- || Cotellic (cobimetinib) / Exelixis, Roche, tiragolumab (RG6058) / Roche, Tecentriq (atezolizumab) / Roche
Trial completion date, Trial primary completion date, Metastases: MORPHEUS-EC: A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) (clinicaltrials.gov) - Apr 27, 2021
P1/2, N=410, Recruiting, Sponsor: Hoffmann-La Roche
Based on the results of this study, mXELIRI was found to be a cost-effective alternative to FOLFIRI as a second-line treatment of mCRC in patients in China. Trial completion date: Feb 2023 --> Feb 2025 | Trial primary completion date: Feb 2023 --> Feb 2025
- | Repatha (evolocumab) / Amgen, Astellas
New P1 trial, Metastases: Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov) - Apr 26, 2021
P1, N=12, Not yet recruiting, Sponsor: CHU de Quebec-Universite Laval
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
[VIRTUAL] Encorafenib plus Cetuximab, with or without Binimetinib, for BRAF V600EPositive Metastatic Colorectal Cancer: Relationship Between Carcinoembryonic Antigen and Clinical Outcomes from BEACON CRC () - Apr 26, 2021 - Abstract #HOPA2021HOPA_135;
P3
Among patients receiving the EBC or EC regimen, lower baseline CEA was associated with longer OS; among patients with the highest baseline CEA, reduction in CEA with treatment was associated with improved OS. The baseline CEA and early on-treatment changes in CEA and CA19-9 levels may potentially identify a subgroup of patients with a numerically greater increase in survival and improved clinical outcomes with targeted therapy for metastatic CRC with BRAF V600E mutation.
- Bavencio (avelumab) / EMD Serono, Pfizer
[VIRTUAL] Efficacy and safety of neoadjuvant short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced rectal adenocarcinoma: Averectal study () - Apr 26, 2021 - Abstract #ESMOGI2021ESMO_GI_116;
P2
Methods This is an investigator-initiated, open-label, single-arm, multicenter, phase II study, adopting Simon s two-stage aiming at evaluating the pCR rate and safety of using short-course radiation therapy (25 Grays in 5 fractions), followed by 6 cycles of mFOLFOX-6 (oxaliplatin, 5-FU and leucovorin) plus avelumab, then total mesorectal excision (TME) 3-4 weeks after last dose in patients with locally-advanced, potentially resectable rectal adenocarcinoma...Conclusions Based on this analysis, the primary endpoint was successfully met with significant improvement in pCR (37.5%, p=0.025) and mpRR rates in the setting of an acceptable safety profile. 3-year disease-free survival and overall survival will be reported later in the final study manuscript.
- [VIRTUAL] Effect of prior bevacizumab treatment in BRAF V600E-mutant metastatic colorectal cancer: Overall survival with encorafenib + cetuximab +/- binimetinib in BEACON CRC () - Apr 26, 2021 - Abstract #ESMOGI2021ESMO_GI_100;
P3
The trial evaluated encorafenib plus cetuximab with or without binimetinib (triplet or doublet, respectively) versus investigators choice of irinotecan or FOLFIRI plus cetuximab (control)...Additional analyses exploring the potential impact of prior bevacizumab use on encorafenib plus cetuximab with or without binimetinib treatment will be presented. Conclusions This exploratory post hoc analysis evaluates OS in patients from BEACON CRC treated with encorafenib plus cetuximab with or without binimetinib to investigate the potential effects of prior bevacizumab treatment on subsequent regimens for patients with BRAF V600E-mutant mCRC.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Zelboraf (vemurafenib) / Roche
[VIRTUAL] 5-FU/LV + cetuximab + vemurafenib as maintenance therapy for BRAF-mutant (BRAFmut) metastatic colorectal cancer: Efficacy, safety, and exploratory biomarker findings from Cohort 1 of the MODUL trial () - Apr 26, 2021 - Abstract #ESMOGI2021ESMO_GI_98;
P2
Methods Control treatment was fluoropyrimidine [FP]/bevacizumab (1600 2400 mg/m 2 5-FU 46-h IV infusion d1 q2w; LV 400 mg/m 2 2-h infusion d1 q2w; or 1000 mg/m 2 bid capecitabine orally d1 14 q3w; bevacizumab 5 mg/kg 15 30-min IV infusion d1 q2w)...Exploratory biomarker findings revealed that selective pressure of the treatment arm leads to acquired mutations that reactivate and converge in the MAPK pathway as drivers of resistance to cetuximab + vemurafenib. Further mutation analyses need to be performed to confirm and identify other mechanisms of resistance to cetuximab + vemurafenib in patients with BRAF mut mCRC that might inform future combination strategies.
- Keytruda (pembrolizumab) / Merck (MSD), Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Final overall survival for the phase 3 KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer () - Apr 26, 2021 - Abstract #ESMOGI2021ESMO_GI_93;
P3
Methods A total of 307 patients with MSI-H/dMMR mCRC and ECOG PS 0 or 1 were randomized 1:1 to 1L pembrolizumab 200 mg Q3W for up to 2y or investigator s choice of mFOLFOX6 or FOLFIRI Q2W bevacizumab or cetuximab...Conclusions As 1L therapy for patients with MSI-H/dMMR mCRC, pembrolizumab vs chemotherapy provides statistically superior PFS with fewer TRAEs, and is associated with a trend toward reduced mortality that did not meet statistical significance likely due to the high crossover rate from chemotherapy to anti-PD1/PD-L1 therapies. Together these data confirm pembrolizumab as a new standard-of-care in the 1L for patients with MSI-H/dMMR mCRC.
- Avastin (bevacizumab) / Roche, napabucasin (BBI608) / Sumitomo Dainippon, Boston Pharma
[VIRTUAL] FOLFIRI ± napabucasin in patients with previously treated metastatic colorectal cancer: Overall survival results from the phase 3 CanStem303C study () - Apr 26, 2021 - Abstract #ESMOGI2021ESMO_GI_92;
P3
Methods CanStem303C (NCT02753127) was a multi-center, open-label, randomized study of patients aged 18 years with histologically confirmed mCRC who failed first-line fluoropyrimidine plus oxaliplatin bevacizumab treatment...Conclusions For patients with previously treated mCRC, the addition of napabucasin to FOLFIRI bevacizumab did not improve OS, PFS, DCR, or ORR in either the GSP or the BM+ population. TEAEs were consistent with previously published data.
- Vectibix (panitumumab) / Amgen, Takeda
[VIRTUAL] Circulating tumor DNA variant allelic fraction as a surrogate for disease burden estimation in patients with RAS wild-type metastatic colorectal cancer: A secondary endpoint of the VALENTINO study () - Apr 26, 2021 - Abstract #ESMOGI2021ESMO_GI_81;
A research grant and drug supply during panitumumab-based maintenance treatment was provided by Amgen...We identified 15.32% as the optimal VAF cut off for survival prediction. Conclusions ctDNA VAF should be prospectively investigated as a prognostic marker and may be useful for estimating disease burden compared to physician experience, CEA and CT scans.
- Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
[VIRTUAL] Treatment sequences and prognostic factors in metastatic pancreatic ductal adenocarcinoma: Univariate and multivariate analyses of a real-world study in Europe () - Apr 26, 2021 - Abstract #ESMOGI2021ESMO_GI_12;
The treatment (trt) sequences were as follows: (trt1) gemcitabine + nab-paclitaxel followed by fluoropyrimidine combinations (n=286); (trt2) (m)FOLFIRINOX followed by gemcitabine combinations (n=263); (trt3) (m)FOLFIRINOX followed by gemcitabine monotherapy (n=228); (trt4) gemcitabine + nab-paclitaxel followed by fluoropyrimidine monotherapy (n=65); (trt5) gemcitabine monotherapy followed by fluoropyrimidine monotherapy (n=41); (trt6) gemcitabine monotherapy followed by fluoropyrimidine combinations (n=32)...Treatment sequences were in accordance with the ESMO guidelines at the time of the study. Liver metastases, treatment sequences, PS, CA19-9, lung metastases and sex were significant independent prognostic factors of OS in this study.
- | Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Enrollment open: AALL1621: Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Apr 26, 2021
P2, N=87, Recruiting, Sponsor: Children's Oncology Group
Liver metastases, treatment sequences, PS, CA19-9, lung metastases and sex were significant independent prognostic factors of OS in this study. Suspended --> Recruiting
- || 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Clinical, Journal: FOLFOX treatment response prediction in metastatic or recurrent colorectal cancer patients via machine learning algorithms. (Pubmed Central) - Apr 24, 2021
Early identification of metastatic or recurrent colorectal cancer (CRC) patients who will be sensitive to FOLFOX (5-FU, leucovorin and oxaliplatin) therapy is very important...Candidate models with the best tuning parameters were applied to the test set and the final model showed satisfactory performance. In addition, we also reported that MLKL and CCDC124 gene expression were independent prognostic factors for metastatic CRC patients undergoing FOLFOX therapy.
- || docetaxel / Generic mfg.
P2 data, Journal: Dose-dense TPF induction chemotherapy for locally advanced head and neck cancer: a phase II study. (Pubmed Central) - Apr 24, 2021
P2
Six cycles of ddTPF is an active, well-tolerated induction regimen for patients with SCCHN. The presence of CR after ICT predicted long-term survival.
- || 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Clinical, P2 data, Journal: Results of Phase II Trial of Intensified Neoadjuvant Treatment with Interdigitating Radiotherapy and Chemotherapy with Oxaliplatin, 5-Fluorouracil and Folinic Acid in Patients with Locally Advanced Rectal Cancer (PROARCT trial). (Pubmed Central) - Apr 24, 2021
Delivery of intensified neoadjuvant treatment with interdigitating chemotherapy and radiotherapy is feasible with no increase in acute perioperative complications. A larger prospective study is required to further evaluate the potential survival benefit of this design.
- || Avastin (bevacizumab) / Roche
Clinical, Journal: Clinical efficacy and safety of second line and salvage aflibercept for advanced colorectal cancer in Akita prefecture. (Pubmed Central) - Apr 24, 2021
A larger prospective study is required to further evaluate the potential survival benefit of this design. AFL can be used to treat advanced CRC patients, with a similar safety and efficacy in the salvage therapy setting as in the second-line setting.
- || BNT321 / BioNTech
Enrollment change: MV-0715-CP-001.01: Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies (clinicaltrials.gov) - Apr 23, 2021
P1, N=162, Recruiting, Sponsor: BioNTech Research & Development, Inc.
AFL can be used to treat advanced CRC patients, with a similar safety and efficacy in the salvage therapy setting as in the second-line setting. N=108 --> 162
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment open: AIPD-1: Transarterial Infusion of PD-1 Antibody Plus TACE-HAIC for Unresectable HCC: a Single-arm, Phase 2 Clinical Trial (clinicaltrials.gov) - Apr 23, 2021
P2, N=80, Recruiting, Sponsor: Sun Yat-sen University
N=108 --> 162 Not yet recruiting --> Recruiting
- || leucovorin calcium / Generic mfg.
Retrospective data, Review, Journal: Efficacy and Safety of High-dose versus Low-dose Leucovorin in Patients with Colorectal Cancer: Systematic Review and Meta-analysis. (Pubmed Central) - Apr 23, 2021
Not yet recruiting --> Recruiting Low-dose leucovorin regimens are seemly feasible approaches for colorectal cancer treatment when the shortage happened, because both regimens manifested comparable outcomes in survival time and tumor response rate.
- || Avastin (bevacizumab) / Roche
Clinical, Journal: Adding Narrow-Band Imaging to Chromoendoscopy for the Evaluation of Tumor Response to Neoadjuvant Therapy in Rectal Cancer. (Pubmed Central) - Apr 23, 2021
Narrow-band imaging is a reliable and promising modality for universal standardization of the diagnosis of clinical complete response. See Video Abstract at http://links.lww.com/DCR/B275.
- ||| docetaxel / Generic mfg.
Clinical, P3 data, Journal: RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV. (Pubmed Central) - Apr 23, 2021
P3
The RACE trial compares induction chemotherapy with FLOT followed by preoperative oxaliplatin and 5-Fluorouracil-based chemoradiation versus preoperative chemotherapy with FLOT alone, both followed by surgery and postoperative completion of FLOT chemotherapy in the treatment of locally advanced, non-metastatic adenocarcinoma of the GEJ. The trial aims to show superiority of the combined chemotherapy/radiochemotherapy treatment, assessed by progression-free survival, over perioperative chemotherapy alone.
- | Avastin (bevacizumab) / Roche
Preclinical, Journal: Combining 1,4-dihydroxy quininib with Bevacizumab/FOLFOX alters angiogenic and inflammatory secretions in ex vivo colorectal tumors. (Pubmed Central) - Apr 23, 2021
The trial aims to show superiority of the combined chemotherapy/radiochemotherapy treatment, assessed by progression-free survival, over perioperative chemotherapy alone. Our results indicate the anti-angiogenic small molecule 1,4-dihydroxy quininib could be an alternative novel treatment in combination therapy for CRC patients.
- | oxaliplatin / Generic mfg., irinotecan / Generic mfg.
Trial primary completion date, Metastases: IRIGA: FOLFOX6 Versus mFOLFIRINOX as First Line Chemotherapy in Metastatic Gastric Cancer or Esophagogastric Junction Adenocarcinoma (Type II-III) (clinicaltrials.gov) - Apr 22, 2021
P2, N=326, Recruiting, Sponsor: Blokhin's Russian Cancer Research Center
Our results indicate the anti-angiogenic small molecule 1,4-dihydroxy quininib could be an alternative novel treatment in combination therapy for CRC patients. Trial primary completion date: Nov 2020 --> Nov 2021
- | oxaliplatin / Generic mfg.
Trial primary completion date: Lidocaine for Oxaliplatin-induced Neuropathy (clinicaltrials.gov) - Apr 22, 2021
P1/2, N=38, Active, not recruiting, Sponsor: Washington University School of Medicine
Trial primary completion date: Nov 2020 --> Nov 2021 Trial primary completion date: Dec 2020 --> Sep 2020
- | veliparib (ABT-888) / AbbVie, Keytruda (pembrolizumab) / Merck (MSD)
Trial primary completion date, Metastases: NRG-GI002: Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer (clinicaltrials.gov) - Apr 22, 2021
P2, N=348, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2020 --> Sep 2020 Trial primary completion date: Mar 2021 --> Mar 2022
- || Depocyte (liposomal cytarabine) / Mundipharma, Leadiant Biosci
Trial primary completion date: Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma (clinicaltrials.gov) - Apr 22, 2021
P2, N=100, Active, not recruiting, Sponsor: University of California, San Diego
Trial primary completion date: Mar 2021 --> Mar 2022 Trial primary completion date: Jan 2024 --> Jul 2020
- | irinotecan / Generic mfg.
Trial initiation date, Combination therapy, Metastases: LIVERPEARL: Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease (clinicaltrials.gov) - Apr 22, 2021
P2, N=48, Not yet recruiting, Sponsor: Grupo Espanol Multidisciplinario del Cancer Digestivo
Trial primary completion date: Jan 2024 --> Jul 2020 Initiation date: Jan 2021 --> Jun 2021
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial completion date, Trial primary completion date, Metastases: Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer (clinicaltrials.gov) - Apr 22, 2021
P2, N=196, Recruiting, Sponsor: Institut f
Initiation date: Jan 2021 --> Jun 2021 Trial completion date: Jun 2022 --> Sep 2022 | Trial primary completion date: Mar 2021 --> Mar 2022
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date, IO biomarker: Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma (clinicaltrials.gov) - Apr 22, 2021
P2, N=40, Recruiting, Sponsor: University of Kansas Medical Center
Trial completion date: Jun 2022 --> Sep 2022 | Trial primary completion date: Mar 2021 --> Mar 2022 Trial completion date: Apr 2021 --> Apr 2023 | Trial primary completion date: Apr 2020 --> Apr 2022
- | Trial completion date, Trial primary completion date, Metastases: Totally Neoadjuvant FOLFOXIRI + Short-course Radiation + XELOX in Patients With Locally Advanced Rectal Cancer (clinicaltrials.gov) - Apr 22, 2021
P2, N=30, Recruiting, Sponsor: China Medical University, China
Trial completion date: Apr 2021 --> Apr 2023 | Trial primary completion date: Apr 2020 --> Apr 2022 Trial completion date: Apr 2021 --> Apr 2022 | Trial primary completion date: Apr 2020 --> Oct 2021
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Trial completion date, Trial primary completion date, Metastases: Pattern of Use of Bevacizumab or Cetuximab + FOLFIRI Regimen as First-line Treatment in Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 22, 2021
P=N/A, N=1800, Recruiting, Sponsor: Joong Bae Ahn
Trial completion date: Apr 2021 --> Apr 2022 | Trial primary completion date: Apr 2020 --> Oct 2021 Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021
- || Trial completion date, Trial primary completion date: MORPHEUS-PDAC: A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) (clinicaltrials.gov) - Apr 22, 2021
P1/2, N=290, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021 Trial completion date: Nov 2021 --> Nov 2022 | Trial primary completion date: Nov 2021 --> Nov 2022
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date, Surgery, Metastases: Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery (clinicaltrials.gov) - Apr 22, 2021
P1b/2, N=68, Suspended, Sponsor: Mayo Clinic
Trial completion date: Nov 2021 --> Nov 2022 | Trial primary completion date: Nov 2021 --> Nov 2022 Trial completion date: Apr 2021 --> Apr 2022 | Trial primary completion date: Apr 2021 --> Apr 2022
- || Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Trial completion date, Trial primary completion date, Combination therapy: A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors (clinicaltrials.gov) - Apr 22, 2021
P1, N=430, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Apr 2021 --> Apr 2022 | Trial primary completion date: Apr 2021 --> Apr 2022 Trial completion date: Sep 2021 --> May 2021 | Trial primary completion date: Sep 2021 --> May 2021